EHA 2023: Selinexor subgroup data from the BOSTON trial highlights its clinical potential in R/R Multiple Myeloma
The Menarini Group (“Menarini”), announced important new data on selinexor at the European Hematology Association (EHA) Congress 2023.…
Browsing: EHA
EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy in which T…
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in fit patients with treatment-naïve chronic lymphocytic leukaemia
Chemoimmunotherapy (CIT) is still standard treatment for patients with chronic lymphocytic leukaemia (CLL), particularly when…
EHA 2022: Quizartinib improves overall survival in adults with FLT3-ITD+ acute myeloid leukaemia
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25%…
EHA 2022: Decitabine shows similar survival and fewer adverse events compared to standard chemo in geriatric AML
Acute myeloid leukaemia (AML) predominantly occurs in older adults over 65 years, who exhibit a…
EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma significantly improves PFS
Mantle cell lymphoma (MCL) is an aggressive type of non-Hodgkin lymphoma that develops from B…
EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutations
Mutations in SF3B1 and U2AF1 can drive overexpression of activated IRAK4 — which regulates inflammation and promotes cancer cell…
EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated CLL
Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) is effective in treating patients with chronic lymphocytic leukaemia (CLL),…